NCI Considers ‘Decentralization’ Of Group C To Provide Wider Access, Local Flexibility
In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut
Lasagna Committee Report Advocates Faster Drug approval, Insurance Coverage For Investigational Drugs, Ancillary Costs
Don’t Blame FDA For All Problems, Broder Says
Outside Experts Might Lengthen NDA Approval, Peck Asserts
Freement Lists Steps For Dealing With Disadvantaged
Trending Stories
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- House passes Mikaela Naylon Give Kids a Chance Act—next step, the Senate
- Harvey Risch, critic of COVID-19 response, tapped by White House to serve as chair of the President’s Cancer Panel
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- Should I have a drink tonight?
In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in - Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it?









